Veracyte is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. Our immuno-oncology diagnostic products and services – formerly HalioDx – help guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies. Leveraging the pioneering work of Dr. Jérôme Galon, the company provides a unique range of immune scoring solutions, including the Immunoscore® assay for assessing the immune contexture of a tumor. Immunoscore® in colon cancer is available as a CLIA or CE marked test to guide day-to-day oncologists’ decisions. Immunoscore® may be a diagnostic platform for additional cancers, as immune response to tumors is a key hallmark of disease progression. We have created a unique biopharmaceutical partnering ecosystem for the identification of clinically relevant biomarker signatures, the demonstration of their clinical utility in trials followed by the development and commercialization of related diagnostic and companion diagnostic tests. Our immuno-oncology experts have developed a complete suite of genomic and proteomic biomarker profiling services, which are based on a world-class data analysis and biostatistics platform to serve the needs of biopharmaceutical companies developing therapeutic antibodies, vaccines, chemotherapies, oncolytic peptides and CAR-T cell therapies. We also provide flexible IVD assay development services for companies in the diagnostics and pharmaceutical industries, as well as for technology providers and clinical labs. Our integrated approach to IVD markets covers contract development, manufacturing, life cycle management and commercialization, as well as integrated quality management system and medical & regulatory affairs support.